Gil Beyen, Erytech CEO

Catal­ent stays hot as it inks deal with French phar­ma that suf­fered PhI­II flop

Just a cou­ple of deals in a cou­ple of days for Catal­ent.

The New Jer­sey-based CD­MO’s lat­est move is a long-term sup­ply agree­ment with Ery­tech Phar­ma, a French clin­i­cal-stage bio­phar­ma, and the pur­chase of its cell ther­a­py man­u­fac­tur­ing site in the moth­er­land.

The deal is good for $44.5 mil­lion, and 40 of Ery­tech’s Prince­ton, NJ em­ploy­ees will be of­fered em­ploy­ment by the site’s new own­er. Catal­ent will now make Ery­tech’s lead can­di­date Gras­pa for clin­i­cal and com­mer­cial sup­ply in the US. Gras­pa is in Phase I tri­als in pa­tients suf­fer­ing from pan­cre­at­ic can­cer right now and is in talks with the FDA for a BLA sub­mis­sion in hy­per­sen­si­tive ALL. That’s tar­get­ed in Q3 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.